About ACEA Biosciences
ACEA Biosciences is a Healthcare company based in San Diego (United States) founded in 2002, and was acquired by Agilent in September 2018. Instruments for life science research are developed and marketed. ACEA Biosciences has raised $37.89 million across 2 funding rounds from investors including Agilent, Qiming Venture Partners and Lilly Asia Ventures. The company has 5,968 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include Cytek Biosciences, Accuri Cytometers and Bioaffinity technologies; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2002 in San Diego, United States, instruments for life science research are developed by ACEA Biosciences. Operations focus on non-invasive technologies, including xCELLigence Real-Time Cell Analysis systems that utilize gold microelectrodes for label-free cell-based assays in multiwell formats. Additionally, the NovoCyte Flow cytometer is marketed to support high-throughput flow cytometry in research settings.
- Headquarters San Diego, United States
- Employees 5,968
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website aceabio.com
- Social LinkedIn X Facebook
- Acquired by Agilent (Sep 2018)
Funding Insights of ACEA Biosciences
ACEA Biosciences has successfully raised a total of $37.89M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $7.89 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.89M
- Total Rounds 2
- Last Round Private Equity Round — $7.89M
- First Round $30M
(Nov 2015)
- Investors Count 2
All 2 funding rounds of ACEA Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $7.89M | Private Equity Round | – | – | – |
| Nov 2015 | $30M | Private Equity Round | – | – |
3 investors in total: 3 institutional.
Investors in ACEA Biosciences
ACEA Biosciences has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Agilent, Qiming Venture Partners and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
| lillyasiaventures.com | ||||
Diversified instruments are developed for scientific and laboratory management. | 1995 | agilent.com | Santa Clara, United States |
Investor details for ACEA Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ACEA Biosciences
4 people are tracked at ACEA Biosciences (2 in leadership, 2 in team); the tracked headcount is 5,968.
| Name | Role | Group |
|---|---|---|
James O' Connell | CEO | Leadership |
Franck Teyssier | Director of Commercialization Europe | Leadership |
Naichen Yu | Account Manager/Technical&Market Support Manager | Team |
gang pan | Marketing Manager | Team |
Complete people profiles for ACEA Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ACEA Biosciences
4 dated milestones of ACEA Biosciences across 16 years, from founding to its latest funding, stage changes and deals.
- Founded ACEA Biosciences is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Private Equity Round, of $7.9M.
- Exit Acquired by Agilent.
Competitors of ACEA Biosciences
ACEA Biosciences has 3 listed competitors in our database, 3 of them funded. They include Cytek Biosciences, Accuri Cytometers and Bioaffinity technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytekbio.com | 2014 | San Francisco, United States | $132M | 676 | Advanced flow cytometry systems are manufactured for research applications. | |
| accuricytometers.com | 2004 | Ann Arbor, United States | $30.91M | Compact flow cytometers for cell analysis are developed and provided. | ||
| bioaffinitytech.com | 2014 | San Antonio, United States | $9.05M | 65 | IVD platforms are developed to detect and target cancer cells. |
Detailed competitors of ACEA Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ACEA Biosciences (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acea Biosciences
Complete news archive for ACEA Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACEA Biosciences
ACEA Biosciences was founded in 2002 and raised its 1st funding round 13 years after it was founded.
ACEA Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
ACEA Biosciences is a funded company, having raised a total of $37.89M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $30M, raised on Nov 2015.
ACEA Biosciences has 5,968 employees.
Founded in 2002 in San Diego, United States, instruments for life science research are developed by ACEA Biosciences. Operations focus on non-invasive technologies, including xCELLigence Real-Time Cell Analysis systems that utilize gold microelectrodes for label-free cell-based assays in multiwell formats. Additionally, the NovoCyte Flow cytometer is marketed to support high-throughput flow cytometry in research settings.
ACEA Biosciences's top competitors include Cytek Biosciences, Bioaffinity technologies and Accuri Cytometers.
ACEA Biosciences has 3 investors. Key investors include Agilent, Qiming Venture Partners, and Lilly Asia Ventures.
Yes. ACEA Biosciences was acquired by Agilent in September 2018.